Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

PharmaCyte Biotech (PMCB) Return on Equity (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Return on Equity for 16 consecutive years, with 0.12% as the latest value for Q1 2026.

  • Quarterly Return on Equity fell 1.0% to 0.12% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.12% through Jan 2026, down 1.0% year-over-year, with the annual reading at 0.07% for FY2025, 3.0% up from the prior year.
  • Return on Equity for Q1 2026 was 0.12% at PharmaCyte Biotech, down from 0.08% in the prior quarter.
  • The five-year high for Return on Equity was 0.04% in Q1 2022, with the low at 0.17% in Q2 2024.
  • Average Return on Equity over 5 years is 0.08%, with a median of 0.07% recorded in 2023.
  • The sharpest move saw Return on Equity skyrocketed 55bps in 2022, then fell -11bps in 2024.
  • Over 5 years, Return on Equity stood at 0.07% in 2022, then fell by -10bps to 0.07% in 2023, then crashed by -44bps to 0.11% in 2024, then increased by 21bps to 0.08% in 2025, then tumbled by -46bps to 0.12% in 2026.
  • According to Business Quant data, Return on Equity over the past three periods came in at 0.12%, 0.08%, and 0.06% for Q1 2026, Q4 2025, and Q3 2025 respectively.